The Lancet published a review by Blakney and colleagues discussing the safety and efficacy of mRNA vaccines. While it aims to examine various scientific and public health aspects, the review has been criticized for its handling of controversies and gaps in evidence.
The review is titled "Safety and efficacy of mRNA vaccines: a mechanistic and public health perspective."
It confidently addresses complex issues like residual DNA and biodistribution but quickly minimizes their significance, creating an illusion of thorough scrutiny.
The authors describe mRNA vaccines as “transformative” with a positive safety profile and conclude that they are safe and effective.
The review is behind a paywall, limiting access for many journalists and policymakers who may rely on its conclusions.
Concerns over biodistribution and residual DNA are noted but not deeply examined, potentially misleading readers into thinking these issues are resolved.
Questions regarding the methods used in safety monitoring and potential adverse events are not adequately addressed, particularly regarding myocarditis and long-term effects.
There is a brief acknowledgment of the lack of sterilizing immunity and modest reductions in transmission, conflicting with earlier public messaging around vaccination and transmission.
The review mentions a shift towards IgG4 antibodies but suggests the clinical implications are uncertain due to inadequate investigation.
Conflicts of interest among the authors, linked to major pharmaceutical companies, raise questions about the impartiality of the review.
The authors attribute declining public trust to misinformation, but they do not address how their own confident messaging may have contributed to this decline.
The review from The Lancet presents itself as an authoritative examination of mRNA vaccines but has significant shortcomings in addressing unresolved questions and potential conflicts of interest, leading to concerns about its reliability as a scientific consensus.
No comments:
Post a Comment